- Patients
- Clinical Research
- Clinical trials
- STARSTRUCK 177Lu-TLX250-001
STARSTRUCK
Open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumours.
Trial overview
Theranostics
Basket - Solid tumours
Ib
Registration number: NCT05868174 https://www.clinicaltrials.gov/study/NCT05868174
|
Murdoch (Oncology)
St John of God Murdoch Hospital, 100 Murdoch Drive, Murdoch, WA, 6150, Australia
(08) 9366 1500 receptiononcologymurdoch@genesiscare.comNuclear Medicine Physician
Dr Aviral Singh
MD PGDipCard MSc FAfNM FRACP - Clinical Head of Theranostics and Nuclear Medicine
Murdoch (Oncology)
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.